Bank of America’s Bone Biologics BBLG Stock Holding History

Bank of America’s Portfolio BBLG Stock Details BBLG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-14	Closed	-$20	–	5807
2025 Q4	$20	Hold	14	–	–	﹤0.01%	7123
2025 Q3	$39	Buy	14 +10	+250%	+$25	﹤0.01%	8066
2025 Q2	$16	Hold	4	–	–	﹤0.01%	8262
2025 Q1	$17	Buy	4 +1	+33%	+$6	﹤0.01%	8158
2024 Q4	$19	Buy	3 +1	+50%	+$8	﹤0.01%	8029
2024 Q3	$30	Hold	2	–	–	﹤0.01%	7903
2024 Q2	$11	Buy	+2	New	+$20	﹤0.01%	8077

Other funds holding BBLG

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Bank of America's BBLG Position: Q1 2026 in Review

Bank of America sold out of Bone Biologics (BBLG) in Q1 2026, closing a stake of 14 shares — an estimated $20 sold.

Bank of America first reported a position in BBLG in Q2 2024 and held it in 7 quarters. The position peaked at $39 in Q3 2025. 3 funds tracked by Wall St. Rank hold BBLG as of Q1 2026.

Bank of America reported no remaining Bone Biologics position as of Q1 2026 after selling out during the quarter.
Bank of America sold 14 Bone Biologics shares in Q1 2026, an estimated $20.
Bank of America first reported a position in Bone Biologics in Q2 2024 and held it in 7 quarters.
Bank of America's Bone Biologics position peaked at $39 in Q3 2025.
3 funds tracked by Wall St. Rank held Bone Biologics as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.